In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Argenx Se, with a price target of $915.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Argenx’s strong market position and future growth potential. The company’s impressive third-quarter report demonstrated continued commercial success, particularly with its product Vyvgart, which has established a significant competitive advantage in its market. Conversations with clinicians further supported the view that Vyvgart is well-positioned within its therapeutic area.
Additionally, Argenx’s development of empasiprubart, a C2 antibody, is expected to enhance its market presence and contribute to its growth. While some investors may perceive the stock as expensive based on 2025 or 2026 sales, the valuation appears reasonable when considering the projected earnings power and operating margins exceeding 50%. The progress of empasiprubart in clinical trials and its recognition among specialists are seen as key factors that could lead to Argenx developing another blockbuster product, reinforcing the company’s narrative and justifying the Buy rating.
In another report released on November 7, J.P. Morgan also maintained a Buy rating on the stock with a $925.00 price target.